anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
MicroRNAs (miRNAs) are a class of non-coding small RNA molecules that regulate gene expression at the post-transcriptional level by interacting with 3' untranslated regions (UTRs) of their target mRNAs. The invention relates to the application of miR-192 and miR-215. Both of these miRNAs impact cellular proliferation through the p53-miRNA circuit, and interact with dihydrofolate reductase (DHFR) and thymidylate synthase (TS). Particularly, upregulation of these miRNAs reduces cellular proliferation. The invention relates to this discovery. For example, inhibiting miR-192 and/or miR-215 sensitizes a neoplasm or a subject with a neoplasm to chemotherapeutic agents. Furthermore, measuring the levels of miR-192 and/or miR-215 provides one with information regarding whether the neoplasm or subject will respond to chemotherapeutic agents. Accordingly, the invention relates to composition and methods relating to the identification, characterization and modulation of the expression of miR-192 and miR-215.
The purpose of this study is to evaluate whether a non-invasive intervention for 3 months with an intermittent compression device (ArtAssist®) in a high risk patient group reduces the risk of subsequent one-year limb-loss and/or death (e.g. one-year amputation-free survival and overall survival.) Survival after an amputation is markedly decreased due to generalized cardiovascular disease. The thirty-day mortality after amputation ranges from 6% to 16% depending on renal function. Two-year mortality after amputation is up to 40%.For dialysis patients, two year mortality was 58%.13 The five-year mortality after amputation in non-renal patients is 65%, while in dialysis patients five-year mortality is 83%. Patients who have undergone a major lower extremity amputation related to vascular disease are also at increased risk for losing their remaining lower extremity. The loss of the second lower extremity has a more profound impact on patients' ability to ambulate or function independently than the first amputation. Despite intensive initial rehabilitation, the use of prosthetics in bilateral amputees decreases rapidly over time. Contra-lateral amputations occur in up to 33%, after a mean of eight months. According to another study, 17% of diabetic initial amputees become bilateral amputees after a median time of less than one year for men and less than two years for women. According to a 2013 study, the majority of the subsequent contra-lateral amputations occur in the first year after the index amputation.

We hope to prove that that there is a role for IPC in vascular patients at high-risk for mortality and limb-loss with relatively low-cost compression therapy. We hope to learn more about which underserved patient categories are most likely to benefit from this and when to start the intervention.
PCT No. PCT/EP88/01083 Sec. 371 Date Aug. 20, 1990 Sec. 102(e) Date Aug. 20, 1990 PCT Filed Nov. 29, 1988 PCT Pub. No. WO90/06299 PCT Pub. Date Jun. 14, 1990.The invention relates to new phenylethanolamines of general formula    <IMAGE>  (I)  wherein A represents a straight-chained or branched alkylene group, B represents a bond, an alkylene group, a carbonyl or hydroxymethylene group, R1 represents a hydrogen atom, a halogen atom or a trifluoromethyl group, R2 represents a hydrogen atom or an amino group, R3 represents a cyano group, a hydrogen, chlorine or bromine atom and R4 represents a hydrogen or halogen atom, an alkyl, hydroxy, alkoxy, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group or an alkoxy group substituted in the end position by a carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, hydroxy, alkoxy, amino, alkylamino, dialkylamino, pyrrolidino, piperidino or hexamethyleneimino group, the optical isomers and diastereoisomers and acid addition salts thereof. The new compounds of formula I, the optical isomers and diastereoisomers and acid addition salts thereof, particularly the physiologically acceptable acid addition salts thereof with inorganic or organic acids, have valuable pharmacological properties, namely an effect on the metabolism, preferably the effect of lowering blood sugar and reducing body fat and they may also be used as performance enhancers in animals. The new compounds of general formula I above may be prepared by methods known per se.
ALDARA Cream should be applied 2 times per week for a full 16 weeks to a defined treatment area on the face or scalp (but not both concurrently). The treatment area is defined as one contiguous area of approximately 25 cm 2(e.g., 5 cm × 5 cm) on the face (e.g., forehead or one cheek) oron the scalp. Examples of 2 times per week application schedules are Monday and Thursday, or Tuesday and Friday. ALDARA Cream should be applied to the entire treatment area and rubbed in until the cream is no longer visible. No more than one packet of ALDARA Cream should be applied to the contiguous treatment area at each application. ALDARA Cream should be applied prior to normal sleeping hours and left on the skin for approximately 8 hours, after which time the cream should be removed by washing the area with mild soap and water. The prescriber should demonstrate the proper application technique to maximize the benefit of ALDARA Cream therapy. 

It is recommended that patients wash their hands before and after applying ALDARA Cream. Before applying the cream, the patient should wash the treatment area with mild soap and water and allow the area to dry thoroughly (at least 10 minutes).

Contact with the eyes, lips, and nostrils should be avoided.

Local skin reactions in the treatment area are common [see Adverse Reactions (6.1, 6.5)]. A rest period of several days may be taken if required by the patient's discomfort or severity of the local skin reaction. However, the treatment period should not be extended beyond 16 weeks due to missed doses or rest periods. Response to treatment cannot be adequately assessed until resolution of local skin reactions. Lesions that do not respond to treatment should be carefully re-evaluated and management reconsidered. 

ALDARA Cream is packaged in single-use packets, with 12 packets supplied per box. Patients should be prescribed no more than 36 packets for the 16-week treatment period. Unused packets should be discarded. Partially used packets should be discarded and not reused.
FIELD: medicine, stomatology. SUBSTANCE: composition consists of two layers and each has silicon dioxide, titanium dioxide, aluminium oxide, boron anhydride, potassium oxide and sodium oxide. The first layer has additionally calcium oxide and the second one has additionally calcium oxide, magnesium oxide and iron oxide and components are taken at the definite ratio. The composition exhibits high strength due to decrease of ceramic mass caking point and retention of high technological properties. EFFECT: improved quality and properties of the composition, decreased cost and availability of the material. 1 cl, 3 ex
24 healthy volunteers will be randomized and will start the study. The study will last 12 weeks for each subject. The first week will be a week of adaptation (or run-in period) to the diet which they will have to follow for the duration of study. During this period, they will collect 3 samples of stools and urine. Then subjects will alternate 4 days of diet either with ham, or with ham and pomegranate extract, or with ham enriched with vitamin E or sirloin steak, marinated sirloin steak or marinated cooked sirloin steak. At least, 3 days will separate every period (wash-out) of nutritional intervention. Urines and stools will be collected last 3 days of every interventional period and also last day of every wash out period.
During HFNC-oxygen, oxygen will be passed through a heated humidifier (AIRVO-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs (Optiflow+ Fisher and Paykel Healthcare), with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep Arterial oxygen saturation (SaO2) \> 90%. Temperature will be adjusted based on patient's comfort and range from 34-37 degrees based on prior experience.
The invention discloses an application of an antifungal drug miconazole in preparing an anti-squamous-lung-carcinoma drug and a cisplatin sensitizer. Because patients with squamous cell lung carcinoma have poor response to common chemotherapeutic drugs and lack of drugs for clinically treating squamous cell lung carcinoma, the development of effective therapeutic drugs is urgently needed. The invention combines the new concept of old medicine, screens the azole antifungal medicines commonly used in clinic and selects the miconazole with the best effect for research. Repeated experiments show that miconazole can reduce active oxygen in cells by inhibiting a PI3K/Akt/NOX4 channel so as to induce apoptosis of squamous cell carcinoma cells and sensitize cisplatin. Meanwhile, in vivo experiments of nude mice also prove that the miconazole has the function of resisting squamous cell lung carcinoma and the effect of sensitizing cisplatin. The invention provides a certain reference for the clinical administration of patients with squamous cell lung carcinoma, and clarifies a mechanism of miconazole for treating squamous cell lung carcinoma.
UNLABELLED: People with Li-Fraumeni syndrome (LFS) harbor a germline pathogenic variant in the TP53 tumor suppressor gene, face a near 100% lifetime risk of cancer, and routinely undergo intensive surveillance protocols. Liquid biopsy has become an attractive tool for a range of clinical applications, including early cancer detection. Here, we provide a proof-of-principle for a multimodal liquid biopsy assay that integrates a targeted gene panel, shallow whole-genome, and cell-free methylated DNA immunoprecipitation sequencing for the early detection of cancer in a longitudinal cohort of 89 LFS patients. Multimodal analysis increased our detection rate in patients with an active cancer diagnosis over uni-modal analysis and was able to detect cancer-associated signal(s) in carriers prior to diagnosis with conventional screening (positive predictive value = 67.6%, negative predictive value = 96.5%). Although adoption of liquid biopsy into current surveillance will require further clinical validation, this study provides a framework for individuals with LFS.
SIGNIFICANCE: By utilizing an integrated cell-free DNA approach, liquid biopsy shows earlier detection of cancer in patients with LFS compared with current clinical surveillance methods such as imaging. Liquid biopsy provides improved accessibility and sensitivity, complementing current clinical surveillance methods to provide better care for these patients. See related commentary by Latham et al., p. 23. This article is featured in Selected Articles from This Issue, p. 5.
BACKGROUND: It is known that many surgeons encounter intraoperative adverse events which can result in Second Victim Syndrome (SVS), with significant detriment to their emotional and physical health. There is, however, a paucity of Asian studies in this space. The present study thus aimed to explore the degree to which the experience of an adverse event is common among surgeons in Singapore, as well as its impact, and factors affecting their responses and perceived support systems.
METHODS: A self-administered survey was sent to surgeons at four large tertiary hospitals. The 42-item questionnaire used a systematic closed and open approach, to assess: Personal experience with intraoperative adverse events, emotional, psychological and physical impact of these events and perceived support systems.
RESULTS: The response rate was 57.5% (n = 196). Most respondents were male (54.8%), between 35 and 44 years old, and holding the senior consultant position. In the past 12 months alone, 68.9% recalled an adverse event. The emotional impact was significant, including sadness (63.1%), guilt (53.1%) and anxiety (45.4%). Speaking to colleagues was the most helpful support source (66.7%) and almost all surgeons did not receive counselling (93.3%), with the majority deeming it unnecessary (72.2%). Notably, 68.1% of the surgeons had positive takeaways, gaining new insight and improving vigilance towards errors. Both gender and surgeon experience did not affect the likelihood of errors and emotional impact, but more experienced surgeons were less likely to have positive takeaways (p = 0.035). Individuals may become advocates for patient safety, while simultaneously championing the cause of psychological support for others.
CONCLUSIONS: Intraoperative adverse events are prevalent and its emotional impact is significant, regardless of the surgeon's experience or gender. While colleagues and peer discussions are a pillar of support, healthcare institutions should do more to address the impact and ensuing consequences.
The present invention relates to identification of agents that play a role in regulating brain amyloid-.beta. (A.beta.) levels in vivo. The invention provides compounds and methods of using such compounds to treat amyloidogenic conditions. It also provides a useful animal model for screening for and evaluating candidate amyloid inhibiting or therapeutic compounds. In particular, ovariectomy (ovx) and estrogen replacement were found to affect brain A.beta. levels in guinea pigs. Long-term ovx of guinea pigs resulted in increased levels of total brain A.beta., as compared to intact animals, and the A.beta.42/A.beta.40 ratio was also elevated. Treatment of ovx guinea pigs with .beta.17-estradiol for ten days partially reversed the ovx-associated increase in brain A.beta. levels.
Participants with a PD-L1 CPS ≥ 10 will receive after randomization ociperlimab + tislelizumab + chemotherapy. The choice of one of three chemotherapy options is at the discretion of the investigator provided that it is either: (1) paclitaxel, (2) nab-paclitaxel, or (3) gemcitabine plus carboplatin.
Wound/bandage protectors configured as a wrap, a sock/mitten, which may be made out of stretchable material. The wrap may have one or more fastening straps as well as possibly a first catch fastening surface. The sock/mitten may have a fastening strap and a sheath. The wrap, the sock/mitten, and the bandages may have apertures and aperture covers. The wrap may have one or more fastening straps as well as possibly a first catch fastening surface and an accessory holder. The sock/mitten may have a fastening strap and a sheath. The strap may be attached to an internal side of a body of the sock/mitten and extend out a slit. The internal portion of the strap having a non-slip grip surface and the external portion of the strip configured to fasten to the body or to the strap itself.
The invention discloses a pharmaceutical composition and a preparation method, a preparation and application thereof. The pharmaceutical composition consists of the following materials in parts by weight: 30-40 parts of resina draconis, 20-30 parts of folium ginkgo, 5-10 parts of rhizoma gastrodiae and 5-10 parts of rhodobryum roseum limp. The preparation method comprises the following steps: crushing and sieving folium ginkgo and rhodobryum roseum limp, and extracting to obtain a folium ginkgo and rhodobryum roseum limp extract; crushing and sieving resina draconis and rhizoma gastrodiae for later use; merging the folium ginkgo and rhodobryum roseum limp  extract with resina draconis and rhizoma gastrodiae, uniformly mixing, and conducting superfine grinding to obtain the target object. The preparation is powder, tablets, capsules, particles, drop pills or honeyed pills, prepared by adding pharmaceutically acceptable auxiliary materials into the pharmaceutical composition. The pharmaceutical composition is applied to preparation of medicines for treating AD. The pharmaceutical composition has the functions of invigorating qi and blood, dispersing blood stasis and relieving depression, restoring consciousness and easing mental stress, improving sleep and preventing and curing AD, has the characteristics of good effect, less toxic or side effects, simple and convenient preparation method and the like, and is suitable for clinical popularization and application.
Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to the left primary motor cortex (M1). Subjects will undergo stimulation once a day for 10 consecutive weekdays.
FIELD: medicine. SUBSTANCE: preparation contains fresh ground St. John's wort, yarrow, calendula and matricary, cudweed herb and plantain leaves mixed with olive oil. All vegetable raw material ingredients are taken in equal quantities. Mass proportion of herbs mixture and vegetable oil is 1:1. Method involves taking the vegetable raw materials, placing it into vegetable oil of foodstuff quality cooled to 0±5 ° C and treating it with mechanical grinding during 0.5-1 min together with the vegetable oil. The so produced mass is strained through gauze to separate large particles and poured into reservoirs to be stored at a temperature not exceeding 0 C. EFFECT: enhanced effectiveness of treatment; accelerated healing and epithelialization of tissues burns, trophic ulcers and other cases. 3 cl
Participants will perform two, 48-hour experimental conditions separated by 24 hours while wearing a continuous glucose monitor to measure glycemic responses. The order of the trials will be randomized for each participant. The two trials will include an exercise condition (EX) and a control, non-exercise condition (CON). During the EX trial, participants will perform four exercise snacks per day on two consecutive days (i.e., Monday and Tuesday). Each exercise snack will be 1-minute in duration and consist of bodyweight style exercise performed with vigorous effort. During the CON trial, participants will be asked to refrain from any structured exercise during two consecutive days (i.e., Thursday and Friday). All meals will be provided to participants during the two 48-hour trials and will be standardized for a given participant. There will be a one-day wash out period in between the completion of both trials for all participants.
This disclosure describes, inter alia, materials, devices, kits and methods that may be used to treat chronic sinusitis. The present disclosure describes various sinus scaffolds having fiber-based and non-fiber-based designs. These designs vary in form, dimension, and delivery location. In addition, therapeutic agent(s) may optionally be included within the scaffolds for local delivery over a brief or extended period of time. Therefore, these scaffolds may be used to improve sinus patency, for example, in surgically modified sinus spaces or in sinus spaces that have not previously undergone surgical modification. Moreover, these scaffolds may be used to deliver local therapeutic agent(s) to such sinus spaces, including, for instance, as part of a treatment program that is an alternative to sinus surgery (e.g., FESS) or in other instances as part of a postoperative care of FESS in some embodiments.
According to the invention preparation for regeneration of bone defects is employed in many branches of medicine, especially in orthopedics, dental surgery, reconstructive surgery, periodonthology and implantology. The preparation has been developed on the basis of inorganic chemical compound naturally occurring, i.e. deproteinized human bone, and on the basis of at least one of inorganic chemical compounds synthetically occurring, i.e. bioglass in the form of granulated high calcium product (54% mol. CaO), obtained with the use of zol-gel method in the system CaO—SiO 2 —P 2 O 5 , of density 2.9082 g/cm 3 , with phase composition with a dominant glassy phase and beginnings of crystallization of apatite, heat treated at temperature of 800° C., having a specific surface BET 57.8166 m 2 /g and/or tricalcium phosphate—TCP in the form of granulated product with chemical formula Ca 3  (PO 4 ) 2 . As a component deproteinized particles of human bone are used, favorably with granulation 0.3-0.5 mm, bioglass favorably with granulation 0.3-0.5 mm and/or TCP—tricalcium phosphate favorably with granulation 0.3-0.5 mm. The amount of bone material in the preparation amounts favorably to 70-80% of the preparation weight, the amount of bioglass in preparation amounts favorably to 10-15% of the preparation weight, the amount of TCP in the preparation amounts favorably to 10-15% of the preparation weight. During implantation binder in the form of blood from patient's operative wound is introduced into the preparation. Amount of the preparation in mixture favorably amounts to 75-80% of the mixture weight and the amount of own blood favorably amounts to 20-25% of the mixture weight.
BACKGROUND: Heart failure (HF) is a disease closely associated with inflammation, and the systemic immune-inflammation index (SII) is a novel inflammatory marker. Therefore, this study aims to explore the relationship between SII and HF.
METHODS: We used National Health and Nutrition Examination Survey data from 1998 to 2018 to include adults who reported a diagnosis of HF and complete information on the calculation of SII. SII was calculated as platelet count × neutrophil count/lymphocyte count. We used multiple logistic regression models to examine the association between SII and HF and explored possible influencing factors by subgroup analysis. In addition, we performed smoothed curve fitting and threshold effect analysis to describe the nonlinear relationship.
RESULTS: The population-based study involved a total of 48,155 adults ages 20-85. Multivariate logistic regression showed that participants with the highest SII had a statistically significant 32% increased risk of HF prevalence compared to those with the lowest SII (OR = 1.32; 95% CI, 1.06-1.65, P = 0.0144) in a fully adjusted model. Subgroup analysis revealed no significant interactions between SII and specific subgroups (p > 0.05 for all interactions). Furthermore, the association between SII and HF was non-linear; the inflection point was 1104.78 (1000 cells/μl).
CONCLUSIONS: Based on our findings, elevated SII levels were found to be strongly associated with the risk of HF, and SII was nonlinearly associated with HF. To validate these findings, a larger prospective investigation is needed to support the results of this study and investigate potential problems.